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Summary Outpatients with tracheostomy can be managed with a low risk for severe
airways infections despite colonization with pathogenic bacteria. No studies have
been focused on chronic obstructive pulmonary disease (COPD), a condition known for
recurrent exacerbations. The aim of our study was to verify whether at follow-up in
tracheostomized COPD versus other disease outpatients, persistent P. aeruginosa
colonization may influence the rate and treatment of lower respiratory tract
infections (LRTI) or hospital admissions. Thirty-nine outpatients were considered: 24
were affected by COPD (age 66, 54–78 years, mean, range), 15 by restrictive lung
disease (RLD) (57, 41–72 years). During an 18-month follow-up the number of LRTIs
were recorded. Bacterial identifications were assessed at baseline and every month
for 6 months in bronchial aspirates. The number of LRTI per patient was not
significantly different between COPD [37, 1(0–6)] and RLD [18, 1(0–5)], [total, median
(range)]. Persistent P. aeruginosa colonized 18 COPD (75%), 12 RLD patients (86%) and
was not associated with an increased number of LRTI: 1(0–6) and 1(0–2), respectively.
There were no differences in the number of hospital admissions: COPD 0(0–2), RLD
1(0–1), with a significant decrease versus before tracheostomy (Po0:001). In
conclusion, the rate of LRTI and hospital admissions in COPD outpatients with chronic
tracheostomy was low, similar to non-COPD patients and independent of P. aeruginosa
colonization.
& 2003 Elsevier Ltd. All rights reserved.
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Introduction
Bronchial microbial colonization is extremely fre-
quent in subjects with chronic tracheostomy.1–4
One of the most represented microrganisms is P.
aeruginosa, a highly adaptable opportunistic hu-
man pathogen able to interact in a complex way
with host cells in both acute and chronic airways
diseases, a paradigmatic condition being cystic
fibrosis.5 Pseudomonas colonization of the airways
has been reported to be associated with severe
bronchial obstruction6 and an increased frequency
and severity of respiratory tract infections7–9 also
in non-cystic fibrosis patients. Although it is a
common belief that tracheostomy leads to an
increased risk of respiratory infections, Harlid
et al.3 clearly demonstrated that patients with
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chronic tracheostomy can be managed at home
with a low risk for developing severe airways
infections despite massive colonization with poten-
tially pathogenic bacteria.
Studies in the literature report data on hetero-
geneous case series. Type of disease and case
history might have an influence on post-tracheost-
omy infections, particularly in chronic obstructive
pulmonary disease (COPD), a condition well known
for repeated exacerbations in its course. The case
series described by Harlid et al.3 included only two
patients with COPD.
We recently reported that patients with chronic
tracheostomy appear to harbour the same micro-
bial flora and display the same type of local soluble
defences, independently of the disease leading to
tracheostomy.4 At that time we had no prospective
data to demonstrate whether or not tracheosto-
mized patients with different disease bear a
different risk of lower respiratory tract infections
(LRTI), particularly in P. aeruginosa carriers.
The aim of the present investigation was to verify
whether at follow-up in tracheostomized COPD
versus restrictive lung disease (RLD) outpatients,
the presence of persistent P. aeruginosa coloniza-
tion may influence the rate and treatment of LRTI,
either bronchitis exacerbations or pneumonia, or
hospital admissions.
Methods
Study population
The study was carried out under the supervision of
the institutional review board at the Scientific
Institute of Rehabilitation in Veruno, Italy.
Thirty-nine outpatients with chronic tracheost-
omy for chronic respiratory failure were considered
in a clinically stable phase: 24 were affected by
COPD, diagnosed according to the American Thor-
acic Society standard criteria10 (age 66, 54–78
years, mean, range; M/F 21/3; months since
tracheostomy 23, 3–62; all former smokers, except
for one current smoker), 15 by pure RLD (12
thoracic wall deformities, three neuromuscular
disease; age 57, 41–72; M/F, 3/12; months since
tracheostomy 22, 2–68; all non-smokers). Recent
antibiotic or corticosteroid treatments (o1 month
prior to study) were among exclusion criteria. Among
COPD patients, 14 were on assist or assist/control
mechanical ventilation during the night and 10 on
long-term oxygen therapy; 12 RLD patients were on
assist or assist/control night-time mechanical venti-
lation and three on long-term oxygen therapy.
Serum albumin levels and total lymphocyte
counts taken as systemic nutritional markers were
in the normal range.
Patients with respiratory disorders other than
COPD, infectious diseases, immunodeficiency con-
ditions, autoimmune disorders, malignancies or
clinically significant haematologic disorders were
excluded.
Only steady-state pharmacologic treatment with
bronchodilators was admitted as well as standard
treatments in the case of chronic heart failure and
diabetes (one case).
No signs of exacerbation (i.e. increase of
cough, expectoration and dyspnea) were present
at the moment of inclusion. Qualitative character-
istics of expectoration were not taken into account
because of their unreliability, since bronchial
secretions in tracheostomized patients are
frequently purulent or mucopurulent at baseline.
The last episode of exacerbation had been
reported more than 1 month before. None of the
patients had been hospitalized within the previous
2 months.
During a follow-up of 18 months, the number of
LRTI and hospital admissions was recorded. Pneu-
monia was defined in the case of an exacerbation
with new infiltrate(s) at chest X-ray, when per-
formed. The information was collected during
periodical visits at our centre scheduled (primarily
for changing the tracheostomy cannula) every 30
days in the first 6 months and every 30–60 days in
the following year. Duration of an exacerbation was
not recorded because of unreliable reporting
(frequent disagreement between patient and
relatives).
A retrospective count of hospital admissions was
performed on file records focusing on the 18
months before tracheostomy.
The global number of antibiotic courses was
recorded in the same follow-up period. According
to patients’ report, antibiotic prescriptions were
classified as appropriate, when signs of exacerba-
tions were evident (worsening of dyspnea and
productive cough), and not appropriate, when
made on the basis of the microbiological
data, but without signs of exacerbation (i.e. ‘‘for
prevention’’ or to eradicate airways bacteria).
Antibiotics given for non-respiratory infections
were registered too, but were not included
in the statistical evaluation. The choice of the
antibiotic was at the general practitioner’s
discretion, but generally based on the antibiogram
of the most recent microbiological test on tracheo-
bronchial aspirate. Oral or parenteral corticoster-
oid courses during an exacerbation were also
registered.
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Bronchial aspirates and processing of
specimens
Tracheobronchial secretions were aspirated me-
chanically in sterile Lukens’ containers (Vygon,
Ecouen, France) through a sterile catheter inserted
in a sterile inner cannula.
All patients had repeated samplings at monthly
intervals for 6 months to evaluate the variations of
the bronchial flora. In the following months,
microbiological evaluations were carried out on
request of the family doctor for clinical purposes,
i.e. targeted antibiotic therapy in case of an
exacerbation.
Bacteriological evaluations
Bacterial counts were assessed with the method of
serial dilutions with saline (104–107 by serial
10-fold dilutions of the original sample). The
medium used was sheep blood agar. Data are
reported as colony forming units (CFU)/ml. When
a single strain is not specified, as in the case of
multiple isolations, CFU refers to the highest
charge independent of the type of bacteria
isolated.
Identification of bacterial strains was performed
with routine methods: rapid ID 32 STREP for
Streptococcacee, ID 32 STAPH for the genera
Staphylococcus, API NH for Neisseria, Haemo-
philus and Branhamella catarrhalis, ID 32 E for
Enterobacteriacee and other Gram-negative
rods, and ID 32 C for yeasts (bioM !erieux sa,
Marcy-l’Etoile, F).
Anaerobe bacteria were not assessed. Persistent
colonization was defined as three or more con-
secutive isolations of the same bacterial strain.
Statistical analysis
Data are reported as geometric mean and range or
median and range, unless otherwise specified. The
Mann–Whitney U test or Student t-test were used
for examining differences between unpaired cate-
gorical or numerical data. Frequency distributions
were compared by chi-square contingency tests
with continuity correction. Regression analysis was
applied to study the correlation between bacterial
charge and number of exacerbations.
AX95% probability was considered statistically
significant. Analyses were performed using a
microcomputer (Macintosh LC) and Stat-viewþ
Graphics software (Abacus Concept).
Results
One patient with RLD and one patient with COPD
died at home after 1 and 12 months, respectively,
for unknown cause. One RLD patient was lost to
follow-up after 4 months for lack of cooperation.
The number of LRTI per patient was not
significantly different between COPD and RLD
patients: 37, 1(0–6) and 18, 1(0–5), [total, median
(range)], respectively.
Persistent colonization with P. aeruginosa was
found in 18 COPD (75%) and 12 RLD patients (86% of
14, excluding one patient who died after 1 month
to whom the definition of persistent colonization
could not be applied). Occasional isolation oc-
curred in four COPD and two RLD patients. There-
fore, in only two COPD and one RLD patients was P.
aeruginosa never isolated. Patients with or without
persistent colonization had a similar number of
LRTI, 1(0–6) and 1(0–2), respectively, P ¼ 0:5;
Mann–Whitney U-test. We found no correlation
between bacterial load and number of exacerba-
tions. Only in one patient with COPD did chest X-ray
document pneumonia.
Type and prevalence of bacterial isolates is
shown in Fig. 1 for the two groups of patients
separately (only the five main strains). Over 6
months the number of isolates for each of the main
strains remained quite stable, in particular for P.
aeruginosa, despite intercurrent antibiotic courses.
Bacterial load variations for the two main bacterial
strains, P. aeruginosa and S. marcescens, are shown
in Table 1. We found no correlation between
bacterial load and months since tracheostomy.
Results of tests for antibiotic sensitivity are
reported in Table 2 limited to the two main strains
isolated and to baseline versus final evaluations. No
particular variations were noted with the exception
of an increased resistance to imipenem/cilastatin
and non-protected piperacilline. This last agent
had been used at home in a number of cases, at a
dose lower than recommended, while no domicili-
ary administration of imipenem/cilastatin was
registered.
At follow-up the number of antibiotic courses did
not differ in the two groups: COPD 67, 2(0–11), RLD
26, 2(0–5) [total, median (range)], including anti-
biotics administered for non-respiratory infections
(8 and 4 courses, respectively). A significantly
higher number of inappropriate antibiotic courses
was prescribed in COPD patients [22, 1(0–4)],
reportedly justified for preventive purposes, i.e.
based on microbiological results, but in the absence
of clinical exacerbation, as compared with RLD
patients [4, 0(0–1)], P ¼ 0:02: There was a sig-
nificant positive correlation between number of
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Table 1 Bacterial load variations over time for the two strains, P. aeruginosa and S. marcescens, accounting for most
isolations (geometric mean and range).
Months P. aeruginosa S. marcescens
0 3.8 105 (1034.2 107) 3.1 105 (3 1031.6 107)
1 2.9 105 (3 1031.6 107) 2.8 105 (3.7 1035.7 106)
2 8.3 105 (1.5 1042.8 107) 2.1 105 (1041.7 107)
3 1.0 106 (1037.2 107) 3.1 105 (1042.0 106)
4 9.4 105 (3.5 1045.4 107) 3.4 105 (1041.8 107)
5 5.3 105 (7.5 1036.0 107) 2.6 105 (3 1039.9 106)
6 2.0 106 (2.9 1037.6 107) 3.2 105 (1031.3 106)
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Figure 1 Type and prevalence of bacterial isolates (only the five main strains) for the two groups of patients
(A¼COPD, B¼RLD).
Table 2 Patterns of antibiotic resistance as percent prevalence of resistant among total strains isolated from the 39
patients under study at baseline (T0) and after 6 months (T6).
Antibiotics P. aeruginosa (26/33) S. marcescens (20/22)
% T0/% T6 % T0/% T6
Ticarcilline 15.4/9.1 40/36.4
Ticarcilline/clavulanate 11.5/3 0/4.5
Piperacilline 11.5/21.2 40/40.9
Piperacilline/tazobactamn 3.8/0 0/0
Ceftazidime 11.5/6.1 15/13.6
Cefsulodine 23.1/18.2 95/95.5
Aztreonam 11.5/9.1 40/31.8
Imipenem/cilastatin 19.2/36.4 0/9.1
Tobramycin 46.2/30.3 65/63.6
Amikacin 0/3 5/9.1
Gentamycin 42.3/30.3 0/0
Netilmycin 38.5/30.3 65/63.6
Colistin 3.8/6.1 95/90.9
Ciprofloxacin 26.9/18.2 0/0
Co-trimoxazole 73.1/48.5 5/0
Only the two main bacteria have been considered (no. of isolates in brackets, baseline/6th month).
nTested in 13 patients only.
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LRTI and frequency of inappropriate antibiotic
courses (r ¼ 0:64; r2 ¼ 0:41; P ¼ 0:002). Corticos-
teroids by general administration were used in only
four COPD patients.
There were no differences in the number of
hospital admissions before tracheostomy between
COPD, 2(0–4), median(range), and RLD patients,
2(1–4). The same was true for the follow-up period
of this study: COPD 0(0–2) versus RLD 1(0–1), but
with a highly significant decrease in the number of
post-tracheostomy hospitalizations compared to
pre-tracheostomy (Po0:001). Analysis of hospital
admissions using the criterion presence/absence of
persistent P. aeruginosa colonization did not give
significant results.
Interestingly, the total number of LRTI was even
lower (Po0:05) than the number of pre-tracheost-
omy hospital admissions, that to a certain degree
reflects the number of severe LRTI.
The comparison of data concerning all the
patients on mechanical ventilation versus all those
on long-term oxygen therapy did not reveal
significant differences in prevalence or charge of
P: aeruginosa, number of LRTI and hospital admis-
sions or antibiotic courses.
Discussion
Previous studies demonstrated that Pseudomonas
colonization is associated with an increased fre-
quency and severity of LRTIs, particularly in the
acute setting8,9 and in subjects with cystic fibrosis,5
but also in long-term tracheostomy patients.7 In our
study, most patients showed persistent colonization
with P. aeruginosa, but this condition was not
associated with an increased number of LRTI. Our
study confirms also for outpatients with COPD, a
condition known for recurrent respiratory infec-
tions, that tracheostomy is not a major risk factor
for respiratory infections despite heavy bacterial
colonization of the large airways.3 Data favourably
compare with the average of two episodes per year
in moderate-to-severe COPD patients without
tracheostomy reported in the literature.6 Even
better, number of hospital admissions were sig-
nificantly decreased in our tracheostomized COPD
patients with respect to before tracheostomy. No
differences were found in number of hospitaliza-
tions with regard to type of disease (COPD or RLD)
or P. aeruginosa colonization. It may be argued that
a bias exists with regard to regular as compared to
‘‘on demand’’ visits, but to counter this would
require a control group with substitution of the
tracheal cannula at random intervals, a protocol
ethically difficult to accept. Our data are some-
what different from those reported by Niederman
et al. in subjects with long-term tracheostomy,7 the
most likely explanation being the inhospital setting
of their study.
Although bacterial infection is one of the main
causes of exacerbations in patients with chronic
respiratory failure, COPD in particular,11 it must be
pointed out that the term exacerbation does not
necessarily imply bacterial infection. On the other
hand, in presence of chronic bacterial colonization
a definite causative link between bacteria and an
exacerbation is quite difficult to prove. For clinical
decision-making this is an important problem and
therapy is in fact often empirical.
Four COPD patients received either oral or
parenteral corticosteroids. The number of subjects
is too low to infer any conclusion about the
influence of corticosteroids on bacteria–host inter-
action or clinical data at follow-up.
Early antibiotic treatment can be clinically
significant in exacerbated severe patients,12 such
as those with chronic respiratory failure, but in our
study 28% of prescriptions were inappropriate (i.e.
only based on microbiological data, in absence of
clinical modifications). Persistent P. aeruginosa
colonization did not influence the rate of prescrip-
tion. It may be argued that we do not know
whether the number of exacerbations in COPD
patients was not significantly higher precisely
thanks to preventive antibiotic treatment. Against
this argument is the positive correlation between
number of LRTI and frequency of inappropriate
antibiotic courses: we would actually expect a
negative correlation should antibiotics be really
effective in preventing exacerbations or no corre-
lation if the two variables are indifferent. An
alternative interpretation is that patients with a
history of frequent LRTI are more likely to be
prescribed an antibiotic course, even in the case of
clinical stability, when sputum analysis is available
introducing a bias towards intervention.
We have already commented on the pattern of
antibiotic resistance in our tracheostomized pa-
tients in a previous paper.4 The only important
variations in time were found for imipenem/
cilastatin and non-protected piperacilline; in the
latter we were able to document administration at
home at inappropriate doses, while imipenem/
cilastatin was probably used during hospital stay at
centres other than ours. The relative stability of
bacterial isolates and antibiotic sensitivity patterns
together with clinical findings led to a remarkable
modification in our long-term management strategy
for tracheostomized patients. Although beyond the
scope of this paper, it is worth reporting that one of
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the practical consequences of this study was an
agreement with family doctors to carry out micro-
biological evaluations only in the case of
clinical deterioration, avoiding any attempt to
eradicate simple airways colonization. This has
led to a sharp reduction in microbiological evalua-
tions and preventive antibiotic courses, without
any increase in the frequency of LRTI and hospital
admissions.
These data may be an important aid in deciding
about tracheostomy as a therapeutic option
for severe COPD and in formulating a correct
antibiotic policy. At the same time, our results
stimulate further research on the factors that
differentiate bacteria–host interaction in the
acute and chronic conditions. As an example,
comparison between virulence intrinsic character-
istics or DNA fingerprinting of pseudomonas
strains responsible for nosocomial infections and
strains simply colonizing the airways is worth
investigation, because patients with chronic colo-
nization may represent an important source of
cross-contamination in case of hospital admis-
sion.13 Furthermore, airways defence mechanisms
in chronic patients may help in finding new
modalities of prevention and treatment for the
acute infections.
In conclusion, the rate of LRTI and hospital
admissions in COPD outpatients with chronic
tracheostomy was low, similar to non-COPD tra-
chestomized patients and independent of persis-
tent P. aeruginosa colonization.
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